Prostate Cancer

Bobby Liaw, MD, presents the case of a 73-year-old man with biochemical recurrence of prostate cancer and metastatic castration-sensitive high-volume disease.

Survival benefit was shown with the combination of niraparib and rucaparib in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

During a conference presentation, A. Oliver Sartor, MD, explained how researchers are building upon the principles of T-cell redirecting agents, such as bispecific T-cell engagers, from other cancer types for the sake of treating patients with prostate cancer.

According to Ajjai S. Alva, MBBS, CDK12 is a cell cycle gene that has an important role in RNA polymerase 2 and immunotherapy activity.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 PROSPER trial of enzalutamide and the phase 3 ARAMIS trial of darolutamide in patients with castration-resistant prostate cancer.

Six months after a 75-year-old patient with castration-resistant prostate cancer shows undetectable PSA, the patient developed new hip pain and urinary frequency.

Daniel P. Petrylak, MD, discusses the impact of the approval of apalutamide in the metastatic castration-sensitive prostate cancer setting.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 SPARTAN trial of apalutamide in patients with castration-resistant prostate cancer.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.

Efficacy signals have been shown in 100% of patients with metastatic prostate cancer treated with a new formulation of cabazitaxel.

Alicia K. Morgans, MD, MPH, discusses how to handle cardiovascular risk factors associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.

Matthew J. Allaway, DO, discusses the need for a safe, precise and efficient option for performing prostate cancer biopsies via the transperineal approach and the limitations with the current standard of care, which is the transrectal approach, during No-Shave November awareness month.

A 75-year-old man presented with intermittent right hip pain, but his physical examination was unremarkable and he had an ECOG performance score of 1. Two oncologists lead a discussion about the patient's case.

A group of oncologists led by Bradley C. Carthon, MD, PhD, discussed clinical work-up, treatment, and follow-up for a 75-year old patents with castration-resistant prostate cancer.

Over abiraterone/prednisone alone, apalutamide plus abiraterone-prednisone proves survival benefit in patients with metastatic castration resistant prostate cancer.

During a live virtual event, Alicia Morgans, MD, MPH, discussed when to combine novel hormonal agents with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer and how novel imaging techniques could influence treatment.

Matthew R. Smith, MD, PhD, discusses areas of unmet needs and clinical pearls for the management of patients with mCRPC.

Prostate cancer expert Dr Smith elaborates on treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on systemic therapy.

Matthew R. Smith, MD, PhD, shares his personal experience using darolutamide for patients with prostate cancer.

Dr Matthew Smith discusses next generation androgen receptor inhibitors and data from clinical trials with these agents.

Prostate cancer expert, Matthew R. Smith, MD, PhD, shares his thoughts about importance of testing in treatment of metastatic castration-resistant prostate cancer (mCRPC).

Dr Matthew R. Smith reviews initial treatment options for a patient with metastatic castration-resistant prostate cancer (mCRPC).

An expert in prostate cancer discusses the typical follow-up and monitoring approaches for a patient with metastatic CRPC.

Matthew R. Smith, MD, PhD, presents the case of a 82-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.